Videos

C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.

Peter Voorhees, MD, discusses the CERVINO trial of the bispecific antibody etentamig that he is presenting at the IMS conference.

Geoffrey Y. Ku, MD, discusses the state of biomarkers in gastric/gastroesophageal junction cancers and where precision medicine still falls short.

Hans Lee, MD, Sarah Cannon Research Institute, explains new IMS/IMWG cure criteria for myeloma and the meaning of durable CAR-T responses in these patients.

Gurbakhash Kaur, MD, discusses how quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping the role of autologous transplant in multiple myeloma.

Shubham Pant, MD, discusses the expanding pipeline of RAS-directed agents beyond daraxonrasib for patients with pancreatic cancer.

Hans Lee, MD, discusses the importance of BCMA-targeted therapy and the differences between CAR T and bispecific antibody therapy in multiple myeloma.

Geoffrey Y. Ku, MD, breaks down HER2-targeted and MSI-high perioperative strategies in gastroesophageal cancer, including new PHERFLOT trial data.

CAR T and bispecific T-cell engagers move earlier in blood cancer care, reshaping sequencing and expanding access beyond academic centers.

Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot predict who will develop them and because on-target effects tend to appear early.

Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that structural overlap in the adenosine triphosphate (ATP) binding pocket makes TRK family inhibition difficult to avoid.

David R. Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design.

Jonathan Villena-Vargas, MD, explains how a team-based training model makes subcostal robotic lung surgery safe, even in complex neoadjuvant cases.

David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low response rates in locally advanced disease.

AI streamlines oncology workflows, cuts admin burden, and hints at smarter interoperability—linking fragmented records for quicker clinical decisions.

E. Anders Kolb, MD, on blood cancer research's legacy in oncology and the racial, geographic barriers still limiting patient access to care.

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.

Saro Armenian, DO, MPH, explains the importance of screening for issues such as secondary skin cancers in patients who received stem cell transplant.

Geoffrey Y. Ku, MD, discusses MATTERHORN, which established perioperative durvalumab plus FLOT as standard care for resectable gastric/GEJ adenocarcinoma.

Jonathan Villena-Vargas, MD, explains how a rib-sparing robotic approach cuts post-thoracotomy pain and opioid use for thoracic surgery patients.

Manojkumar Bupathi, MD, MS, discusses the changes that biomarker-based treatment brings to hormone-sensitive prostate cancer.

Martin Dietrich, MD, PhD, says duration of response and progression-free survival converge in the untreated setting, because response rates approach the whole population, so the two numbers carry much the same information.

Wade Iams, MD, frames central nervous system management around radiation sparing.

MSOs and physician networks streamline oncology practice operations, cut administrative burden, and preserve autonomy—helping community oncologists focus on patients and reduce burnout.

Gavin Wright, MBBS, explains what the phase 3 VISUALIZE 2 trial aims to confirm about abenacianine's surgical benefit for patients with lung cancer.

David DiBardino, MD, explains why intratumoral therapy emerged in lung cancer and the open questions in standardizing how it's delivered to tumors.

Oncologists share practical ways to spot burnout early, set boundaries, boost recognition, and protect work-life balance across your career.

Geoffrey Y. Ku, MD, explains the latest developments with bispecific antibodies in patients with gastric and gastroesophageal junction cancers.

Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.

Manojkumar Bupathi, MD, MS, discusses the key trials that have made a splash in prostate cancer in the last year.